ACR Convergence 2020: Presentations on KZR-616 for Autoimmune Conditions
https://pixabay.com/photos/student-typing-keyboard-text-woman-849822/

ACR Convergence 2020: Presentations on KZR-616 for Autoimmune Conditions

Since the company was founded, biotechnology company Kezar Life Sciences ("Kezar") has worked to develop therapies for patients with oncologic and autoimmune disorders. Recently, they highlighted a potential treatment, KZR-616,…

Continue Reading ACR Convergence 2020: Presentations on KZR-616 for Autoimmune Conditions
Meta Analysis Shows MMF Provides Greater Benefit to Lupus Nephritis Patients Than CYC
source: pixabay.com

Meta Analysis Shows MMF Provides Greater Benefit to Lupus Nephritis Patients Than CYC

A recent study, published in the journal Medicine, has found that Mycopheenolate mofetil (MMF) could be a more advantageous therapy for lupus nephritis than cyclophosphamide (CYC) when it comes to improving serum complement…

Continue Reading Meta Analysis Shows MMF Provides Greater Benefit to Lupus Nephritis Patients Than CYC
Safe Pregnancies with Rheumatic Diseases are Possible with Planning
source: pixabay.com

Safe Pregnancies with Rheumatic Diseases are Possible with Planning

Dr. Lisa Sammaritano from Weill Cornell Medical College has explained a way to lower risks within pregnancy for those with rheumatic diseases. Pregnancy and Rheumatic Diseases Patients who have a…

Continue Reading Safe Pregnancies with Rheumatic Diseases are Possible with Planning
Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
source: pixabay.com

Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years

  Dr. Richard Furie at New York’s Feinstein Institutes recently interviewed with MedPage Today. Dr. Furie discussed the prognosis for lupus nephritis and belimumab (Benlysta), a recently-tested drug that appears…

Continue Reading Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
This Criteria Helps Predict Chronic Kidney Disease in Lupus Nephritis Patients
source: pixabay.com

This Criteria Helps Predict Chronic Kidney Disease in Lupus Nephritis Patients

Lupus nephritis causes kidney inflammation and can often lead to chronic kidney disease (CKD). An issue that medical professionals have faced is predicting the likelihood of individual patients developing CKD.…

Continue Reading This Criteria Helps Predict Chronic Kidney Disease in Lupus Nephritis Patients
Lupus Nephritis Biomarkers Highlight Race-Based Differences
https://pixabay.com/en/hand-united-together-people-unity-1917895/

Lupus Nephritis Biomarkers Highlight Race-Based Differences

When studying biomarkers of lupus nephritis, researchers at the University of Houston discovered something interesting: race-based differences. Biomarkers are some sort of measurable substance; in this case, urinary proteins. However,…

Continue Reading Lupus Nephritis Biomarkers Highlight Race-Based Differences

AURORA Study Finds Voclosporin Effective for Lupus Nephritis Treatment

  According to an article in Healio, the immunosuppressing drug voclosporin was found to be effective in stimulating renal responses in patients with lupus nephritis. About Lupus Nephritis Lupus nephritis…

Continue Reading AURORA Study Finds Voclosporin Effective for Lupus Nephritis Treatment

Pediatric Cancer and the 70th Anniversary of the Leukemia & Lymphoma Society

  When the Leukemia & Lymphoma Society (LLS) was founded in 1949 by a family in memory of their sixteen-year-old son, cancer was considered a hopeless condition. As noted recently…

Continue Reading Pediatric Cancer and the 70th Anniversary of the Leukemia & Lymphoma Society
Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial
source: pixabay.com

Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial

According to a story from BioPortfolio, the biopharmaceutical company Aurinia Pharmaceuticals, Inc. has recently announced positive findings from its phase 3 clinical trial of the experimental drug voclosporin, which was…

Continue Reading Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial

Failure of Promising Investigatory Lupus Drug Prompts Discussion to Improve Clinical Trials

According to a publication from The Rheumatologist, the recent failure of a seemingly-promising lupus treatment in a phase 2 study has led to a discipline-wide discussion about new research and…

Continue Reading Failure of Promising Investigatory Lupus Drug Prompts Discussion to Improve Clinical Trials
In Studying Lupus Nephritis, These Scientists are Taking Biopsies to the Next Level
kkolosov / Pixabay

In Studying Lupus Nephritis, These Scientists are Taking Biopsies to the Next Level

According to a story from EurekAlert!, a team of researchers studying lupus nephritis, a kidney disease that can affect people diagnosed with lupus, are utilizing a highly precise new tool…

Continue Reading In Studying Lupus Nephritis, These Scientists are Taking Biopsies to the Next Level
Ongoing Research Aims to Improve Monitoring and Detection for Lupus Nephritis
FotoshopTofs / Pixabay

Ongoing Research Aims to Improve Monitoring and Detection for Lupus Nephritis

According to a story from news-medical.net, a pair of researchers affiliated with the University of Houston are planning to dedicate their time to improving detection and monitoring of lupus nephritis,…

Continue Reading Ongoing Research Aims to Improve Monitoring and Detection for Lupus Nephritis

New Potential Treatment for Systemic-Onset Juvenile Idiopathic Arthritis Investigated in China

SOJIA SOJIA stands for systemic-onset Juvenile Idiopathic Arthritis (JIV). It is a very severe form of JIA which causes joint pain, inflammation, recurrent fevers, and a skin rash. Patients often take predinsolone,…

Continue Reading New Potential Treatment for Systemic-Onset Juvenile Idiopathic Arthritis Investigated in China

Phase 1b Trial for Lupus Nephritis Utilizing New Therapeutic Approach to Commence Soon

Lupus Nephritis Lupus nephritis (LN) is one of the most common complications of systemic lupus erythematosus (SLE). It affects approximately 100,000 patients in the United States alone. Basically, the patient's…

Continue Reading Phase 1b Trial for Lupus Nephritis Utilizing New Therapeutic Approach to Commence Soon

Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…

Continue Reading Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy
Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment
Source: Pixabay

Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment

According to Business Wire, a pharmaceutical company, Aurinia Pharmaceuticals Inc., recently announced that they have enrolled the first lupus nephritis patients in the AURORA 2 extension study. Not only this, but Aurinia…

Continue Reading Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment
Close Menu